汇宇制药(688553)披露与阿斯利康达成临床研究合作,1月9日股价上涨6.8%

中金财经
Jan 10

  h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2026年1月9日收盘,汇宇制药(688553)报收于22.0元,较前一交易日上涨6.8%,最新总市值为93.19亿元。该股当日开盘20.6元,最高22.1元,最低20.37元,成交额达3.16亿元,换手率为4.32%。公司近日发布公告称,其全资子公司汇宇海玥与阿斯利康签署《临床试验合作协议》,就自主研发的I类创新药HYP-6589片与阿斯利康的奥希替尼联合治疗特定类型非小细胞肺癌的临床研究展开合作。合作内容包括评估HYP-6589单药及联合奥希替尼的安全性、耐受性、药代动力学和有效性。公告指出,该合作有助于加快公司创新药临床试验进程,提升研发效率,节约时间和成本。本次合作不构成重大资产重组,无需提交公司董事会或股东会审议,预计不会对公司财务状况和经营成果产生重大影响。最新公告列表《自愿披露关于与阿斯利康达成临床研究合作的公告》为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10